Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease

Journal of the American Society of Nephrology

Volumn 14, Issue 7, 2003, Pages 1738-1747

  Huang, Xiao R ^a   Chen, Wei Y ^b   Truong, Luan D ^a   Lan, Hui Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CHYMASE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY CELL; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; UPREGULATION;

EID: 0037967318     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000071512.93927.4E     Document Type: Article

References (35)

1. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K: Mechanisms of diabetic vasculopathy: An overview. Am J Hypertens 14: 475-486, 2001
2. Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 77: S93-S98, 2000
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
5. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
6. Brenner BM, Cooper ME, de Zeeuw DK, William FM, William E, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
7. Siragy HM, Howell NL, Ragsdale NV, Carey RM: Renal interstitial fluid angiotensin. Modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension 25: 1021-1024, 1995
8. Van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser AH: Intrarenal angiotensin II: Interstitial and cellular levels and site of production. Kidney Int 60: 2311-2317, 2001
9. Dell'Italia LJ, Husain A: Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol 17: 374-379, 2002
10. Miyazaki M, Takai S: Local angiotensin II-generating system in vascular tissues: The roles of chymase. Hypertens Res 24: 189-193, 2001
11. Takai S, Yuda A, Jin D, Nishimoto M, Sakagichi M, Sasaki S, Miyazaki M: Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett 467: 141-144, 2000
12. Takai S, Jin D, Nishimoto M, Yuda A, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Sasaki S, Miyazaki M: Oral administration of a specific chymase inhibitor. NK 3201: inhibits vascular proliferation in grafted vein. Life Sci 69: 1725-1732, 2001
13. Richard V, Hurel-Merle S, Scalbert E, Ferry G, Lallemand F, Bessou JP, Thuillez C: Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 104: 750-752, 2001
14. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ: Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37: 1056-1061, 2001
15. Wei CC, Tian B, Perry G, Meng QC, Chen YF, Oparil S, Dell'Italia LJ. Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am J Physiol Heart Circ Physiol 282: H2254-H2258, 2002
16. Lan HY, Mu W, Nickolic-Paterson DJ, Atkins RC: A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43: 97-102, 1995
17. Urata H, Boehm KD, Philip A: Cellular-localization and regional distribution of an angiotensin-II-forming chymase in the heart. J Clin Invest 91: 1269-1281, 1993
18. Cao ZM, Hulthen UL, Allen TJ, Cooper ME: Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action. J Hypertens 16: 793-799, 1998
19. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M: Marked species-difference in the vascular angiotensin II-forming pathways: Human versus rodents. Jpn J Pharmacol 62: 207-210, 1993
20. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M: Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 412: 86-90, 1997
21. Ju H, Gros R, You X, Tsang S, Husain M, Rabinovitch M: Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci USA 98: 7469-7474, 2001
22. Miyazaki M, Wada T, Shiota N, Takai S: Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 12[suppl 1]: S21-S25, 1999
23. Yamada M, Ueda M, Naruko T, Tanabe S, Han YS, Ikura Y, Ogami M, Takai S, Miyazaki M: Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int 59: 1374-1381, 2001
24. Shiota N, Jin D, Takai S, Kawamura T, Koyama M, Nakamura N, Miyazaki M: Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension. FEBS Lett 406: 301-304, 1997
25. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME: Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Lond) 100: 591-599, 2001
26. Wilkinson-Berka JL, Gibbs NJ, Cooper ME, Skinner SL, Kelly DJ: Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant 16: 1343-1349, 2001
27. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444, 2000
28. Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O'Dorisio TM: Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 19: 1-6, 1999
29. Kalender B, Ozturk M, Tuncdemir M, Uysal O, Dagistanli FK, Yegenaga I, Erek E: Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Acta Histochem 104: 123-130, 2002
30. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38: 18-25, 2001
31. Kincaid-Smith P, Fairley K, Packham D: Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 17: 597-601, 2002
32. Hilgers KF, Mann JFE: ACE Inhibitors versus AT1 receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 13: 1100-1108, 2002
33. Ferrari P, Marti HP, Pfister M, Frey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 20: 125-130, 2002
34. Remuzzi A, Gagliardini E, Donadoni C, Fassi A, Sangalli F, Lepre SM, Remuzzi G, Benigni A: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 62: 885-894, 2002
35. Remuzzi G: ACE inhibitor and AT1 receptor antagonists: Is two better than one? Kidney Int 61: 1545-1547, 2002